Receptor News and Research

RSS

Phase IIa clinical trial data of ATL1102 in MS patients published in journal Neurology

Antisense Therapeutics is pleased to report the publication of previously generated Phase IIa clinical trial data on ATL1102 in the medical journal Neurology.

22 Sep 2014

Biosensor opens up possibility of rapid, point-of-care diagnostic tool for cancer patients

An ultrasensitive biosensor made from the wonder material graphene has been used to detect molecules that indicate an increased risk of developing cancer.

22 Sep 2014

Researchers discover key cell-signaling pathway that contributes to development of Alzheimer's disease

Researchers at Jacksonville's campus of Mayo Clinic have discovered a defect in a key cell-signaling pathway they say contributes to both overproduction of toxic protein in the brains of Alzheimer's disease patients as well as loss of communication between neurons - both significant contributors to this type of dementia.

21 Sep 2014

People who experience migraine in middle age may develop movement disorders later in life

A new study suggests that people who experience migraine in middle age may be more likely to develop Parkinson's disease, or other movement disorders later in life. Those who have migraine with aura may be at double the risk of developing Parkinson's, according to the study published in the September 17, 2014, online issue of Neurology, the medical journal of the American Academy of Neurology.

18 Sep 2014

Study suggests potential treatment for cardiovascular disease in people with apoE4 gene variant

Researchers at UT-Southwestern Medical Center have found that the most common variant of the circulating protein apolipoprotein E, called apoE3, helps repair the lining of blood vessels. Individuals with another variant, called apoE4, do not get the benefit of this repair, putting them at higher risk for cardiovascular disease.

18 Sep 2014

Rosuvastatin promotes bone growth in mice with achondroplasia symptoms

Skeletal dysplasia is a group of rare diseases that afflict skeletal growth through abnormalities in bone and cartilage. Its onset hits at the fetal stage and is caused by genetic mutations.

18 Sep 2014

Ramucirumab effective second-line option for NSCLC

The monoclonal antibody ramucirumab, when added to second-line docetaxel, significantly improves the overall survival of patients with stage IV non-small-cell lung cancer, show the findings of the REVEL trial.

17 Sep 2014

Survival benefits with erlotinib plus bevacizumab in EGFR-Mutated NSCLC

Combining erlotinib with bevacizumab could prolong progression-free survival in patients being treated for epidermal growth factor receptor-mutated non-small-cell lung cancer, phase II trial results suggest.

17 Sep 2014

Sacral neuromodulation augments efficacy of antimuscarinics in OAB

The addition of sacral neuromodulation to antimuscarinic pharmacotherapy offers significant benefits over antimuscarinics alone in the treatment of women with idiopathic overactive bladder, study findings show.

17 Sep 2014

Radiation and endocrine therapy combination may not be necessary for all HR+ breast cancer patients

Treatment with endocrine therapy and radiation therapy as part of breast conservation is the current standard of care for women with hormone-receptor positive (HR+) invasive breast cancer. A new study by researchers at Fox Chase Cancer Center, however, shows that combination may not be necessary for all patient populations with the disease.

17 Sep 2014

Parous women have higher chance of developing estrogen receptor-negative breast cancer

Women who have had children (parous women) appear to have an increased risk of developing estrogen receptor-negative breast cancer, the subtype that carries a higher mortality rate and is more common in women of African ancestry.

17 Sep 2014

OGT to highlight NGS and FISH methods for tumour screening at BSGM 2014

Oxford Gene Technology, The Molecular Genetics Company, is inviting attendees of the British Society for Genetic Medicine annual conference to its seminar entitled ‘Approaches to tumour screening and therapy stratification: case studies in Non-Small Cell Lung Cancer’ on Monday 22nd September, 13.10-13.50, room 2N.

From Oxford Gene Technology 17 Sep 2014

New study sheds light on relationship between schizophrenia and smoking stems

Schizophrenia is associated with increased rates and intensity of tobacco smoking. A growing body of research suggests that the relationship between schizophrenia and smoking stems, in part, from an effort by patients to use nicotine to self-medicate symptoms and cognitive impairment associated with the disease.

17 Sep 2014

New method helps reveal secret dance of proteins

Staying clear of diseases requires that the proteins in our cells cooperate with one another. But, it has been a well-guarded secret how tens of thousands of different proteins find the correct dancing partners as they degrade and build up the human body, brain and nervous system.

17 Sep 2014

MOVANTIK tablets get FDA approval for treatment of OIC in patients with chronic, non-cancer pain

Nektar Therapeutics reported today that partner AstraZeneca today announced that the US Food and Drug Administration (FDA) approved MOVANTIK (naloxegol) tablets as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain.

16 Sep 2014

Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for castration-resistant prostate cancer

Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with ODM-201, an investigational oral androgen receptor inhibitor in clinical development.

16 Sep 2014

Amgen announces phase 3 ivabradine data for treatment of chronic HF

Amgen (NASDAQ: AMGN) today announced data from the Phase 3 SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) study evaluating ivabradine in patients with chronic heart failure (HF) were presented at the 18th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) in Las Vegas.

15 Sep 2014

Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Eli Lilly and Company today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival.

15 Sep 2014

Researchers hope to find new ways to combat age-related diseases

Through the study of the roundworm, Caenorhabditis elegans, the team led by Hugo Aguilaniu has discovered a hormone that enhances longevity and reduces fertility, thus reproducing the effects of an extreme diet.

11 Sep 2014

Researchers show how activation of receptor provokes bone degradation of rheumatoid arthritis

Researchers at the University of Illinois at Chicago College of Medicine have shown for the first time how the activation of a receptor provokes the inflammation and bone degradation of rheumatoid arthritis -- and that activation of this one receptor, found on cells in the fluid of arthritic joints, is all that is required.

11 Sep 2014

Receptor News and Research

Phase IIa clinical trial data of ATL1102 in MS patients published in journal Neurology

Biosensor opens up possibility of rapid, point-of-care diagnostic tool for cancer patients

Researchers discover key cell-signaling pathway that contributes to development of Alzheimer's disease

People who experience migraine in middle age may develop movement disorders later in life

Study suggests potential treatment for cardiovascular disease in people with apoE4 gene variant

Rosuvastatin promotes bone growth in mice with achondroplasia symptoms

Ramucirumab effective second-line option for NSCLC

Survival benefits with erlotinib plus bevacizumab in EGFR-Mutated NSCLC

Sacral neuromodulation augments efficacy of antimuscarinics in OAB

Radiation and endocrine therapy combination may not be necessary for all HR+ breast cancer patients

Parous women have higher chance of developing estrogen receptor-negative breast cancer

OGT to highlight NGS and FISH methods for tumour screening at BSGM 2014

New study sheds light on relationship between schizophrenia and smoking stems

New method helps reveal secret dance of proteins

MOVANTIK tablets get FDA approval for treatment of OIC in patients with chronic, non-cancer pain

Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for castration-resistant prostate cancer

Amgen announces phase 3 ivabradine data for treatment of chronic HF

Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Researchers hope to find new ways to combat age-related diseases

Researchers show how activation of receptor provokes bone degradation of rheumatoid arthritis

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News